BioCurex, Inc.(fka BOCX)

[HALF FULL GLASS]

Well Bocxman I have been saying for a long time that this stock should be trading at $100 per share. If you could summarize your last post into a few words it would probably explain why the stock is under $1.00.

This is directly off of Abbotts web page...I don't think they want it for just a small niche !!

Because many cancer deaths may be prevented with early screening and treatment, it's important to develop new cancer tests that could more effectively target a specific type of cancer. Preliminary studies indicate that RECAF may provide good clinical sensitivity and specificity as a tumor marker," said William Brown, Ph.D., vice president, Diagnostic Assays and Systems Development, Abbott. "Abbott's goal is to further develop this technology, incorporating it into future tests on our ARCHITECT ® system, for use in cancer diagnosis and monitoring."

Under terms of the agreement, Abbott obtains worldwide, semi-exclusive rights to commercialize products using BioCurex's RECAF technology. The agreement includes payment to BioCurex of up-front fees, product development milestones and royalties on any product sales. Other terms of the agreement were not disclosed.

http://abbottdiagnostics.com/About_Us/pressrelease.cfm?pr_id=60